Observational study on risk factors for progressive pulmonary fibrosis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to investigate the risk factors, prevalence, and mortality associated with progressive pulmonary fibrosis (PPF) in patients with interstitial lung disease (ILD). Participants will undergo baseline assessments, including demographic data, medical history, and various lung function tests, along with blood sampling. Follow-up visits at 6 and 12 months will repeat these assessments to track changes over time. The study focuses on patients with radiological evidence of pulmonary fibrosis, excluding those with idiopathic pulmonary fibrosis.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* 18-80 years old
* Agree and sign the informed consent form
* Interstitial lung disease patients with imaging features of pulmonary fibrosis

Exclusion Criteria:

* Patients with idiopathic pulmonary fibrosis (IPF)
* Pregnant or lactating women
* mental illness or cognitive impairment
* participating in other clinical studies
* Unable to sign informed consent form

Where it's running

• The First Affiliated Hospital of Shandong First Medical University
  Jinan, Shandong, China Recruiting

Study contacts

• Study coordinator: zhi guo, Doctor
• Email: guozhi770217@163.com
• Phone: +8613853120761

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Telitacicept for primary Sjögren’s with interstitial lung disease

  This study tests whether Telitacicept helps people with primary Sjögren’s syndrome and interstitial lung disease compared with standard immunosuppressants.

  Recruiting Peking University People's Hospital · Beijing · NCT07843381

• Inhaled mosliciguat for pulmonary hypertension in interstitial lung disease (PH-ILD) patients

  This study tests inhaled mosliciguat versus placebo in people with PH-ILD to see if it helps with their condition.

  Recruiting at 3 sites Phase 3 Pulmovant, Inc. · Kissimmee, Florida and 2 other locations · NCT07816185

• Treprostinil Palmitil Inhalation Powder for Progressive Pulmonary Fibrosis

  A 52-week study will test whether once-daily Treprostinil Palmitil Inhalation Powder helps lung function in adults with progressive pulmonary fibrosis compared to placebo.

  Recruiting Phase 3 Insmed Incorporated · DuBois, Pennsylvania · NCT07805785

• Treatment Response in Myositis-Associated RP-ILD in Adults

  This study tests how people with myositis and rapidly progressing interstitial lung disease respond to an immunosuppressant treatment approach.

  Recruiting Singapore General Hospital · Singapore · NCT07775235

• AccuPulmo CT Portal for Detecting Pulmonary Fibrosis on Chest CT

  This study tests how well the AccuPulmo CT Portal can identify pulmonary fibrosis on existing chest CT scans from adults at Taichung Veterans General Hospital.

  Recruiting Taichung Veterans General Hospital · Taichung · NCT07761377

• See if 18F-FAPI-74 PET/CT can better detect fibrosis in heart and lung disease

  Researchers are testing a new PET/CT tracer, 18F-FAPI-74, to see if it can reveal early fibrotic changes in people with heart and lung diseases who are at risk for tissue scarring.

  Recruiting Phase 3 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07613099

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.